These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24518207)

  • 1. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
    Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
    Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
    Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
    Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
    Ziouti F; Rummler M; Steyn B; Thiele T; Seliger A; Duda GN; Bogen B; Willie BM; Jundt F
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
    Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
    Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
    Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.
    Shinohara M; Chang BY; Buggy JJ; Nagai Y; Kodama T; Asahara H; Takayanagi H
    Bone; 2014 Mar; 60():8-15. PubMed ID: 24316417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase: oncotarget in myeloma.
    Tai YT; Anderson KC
    Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Marine J; Miranda M; Azaryan A; Yu X; Nava-Parada P; Mei J; Kipps TJ
    Haematologica; 2016 Jul; 101(7):e295-8. PubMed ID: 27151992
    [No Abstract]   [Full Text] [Related]  

  • 11. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
    Evans EK; Tester R; Aslanian S; Karp R; Sheets M; Labenski MT; Witowski SR; Lounsbury H; Chaturvedi P; Mazdiyasni H; Zhu Z; Nacht M; Freed MI; Petter RC; Dubrovskiy A; Singh J; Westlin WF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):219-28. PubMed ID: 23709115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
    Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
    Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
    Bam R; Venkateshaiah SU; Khan S; Ling W; Randal SS; Li X; Zhang Q; van Rhee F; Barlogie B; Epstein J; Yaccoby S
    Blood Cancer J; 2014 Aug; 4(8):e234. PubMed ID: 25083818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
    Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis.
    Pandey MK; Gowda K; Sung SS; Abraham T; Budak-Alpdogan T; Talamo G; Dovat S; Amin S
    Exp Hematol; 2017 Sep; 53():31-42. PubMed ID: 28647392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.